1
|
Sugrue A, Ibrahim R, Lu M, Bhatia NK, Alkukhun L, Adewumi J, Schaller RD, Marchlinski FE, D'Souza B, Nazer B, Tzou W, Merchant FM, Frankel DS. Impact of Median Sternotomy on Safety and Efficacy of the Subcutaneous Implantable Cardioverter Defibrillator. Circ Arrhythm Electrophysiol 2023; 16:468-474. [PMID: 37485688 DOI: 10.1161/circep.123.011867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Accepted: 07/16/2023] [Indexed: 07/25/2023]
Abstract
BACKGROUND Subcutaneous implantable cardioverter defibrillators (S-ICDs) are an attractive alternative to transvenous ICDs among those not requiring pacing. However, the risks of damage to the S-ICD electrode during sternotomy and adverse interactions with sternal wires remain unclear. We sought to determine the rates of damage to the S-ICD lead during sternotomy, inappropriate shocks from electrical noise due to interaction with sternal wires, and failure to terminate spontaneous or induced ventricular arrhythmias. METHODS Retrospective, multicenter study of patients undergoing sternotomy before or after S-ICD implantation. Clinical, procedural, and device-related data were collected by each center and analyzed by the coordinating center. These data were compared with a historical control cohort of nonsternotomy patients. RESULTS Of 196 identified patients (52±16 years, 47 women), 166 underwent S-ICD implantation after sternotomy and 30 sternotomy after S-ICD. There was no damage to any lead among those who underwent sternotomy after S-ICD. Defibrillation threshold testing was performed in 63% at implant, with 91% first shock success. During a median follow-up of 29 months (range, 1-188), S-ICD first shocks successfully terminated spontaneous ventricular arrhythmias in 31 of 32 patients (97%). Inappropriate shocks occurred in 22 patients, most commonly related to T wave oversensing (n=14). Compared with the nonsternotomy controls, there were no differences in rates of first shock success for induced or spontaneous arrhythmias or rate of inappropriate shocks. CONCLUSIONS Sternotomy before or after S-ICD does not confer additional risk relative to a historical control group without sternotomy.
Collapse
Affiliation(s)
- Alan Sugrue
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
| | - Rand Ibrahim
- Section of Cardiac Electrophysiology, Emory University School of Medicine, Atlanta, GA (R.I., M.L., N.K.B., F.M.M.)
| | - Marvin Lu
- Section of Cardiac Electrophysiology, Emory University School of Medicine, Atlanta, GA (R.I., M.L., N.K.B., F.M.M.)
| | - Neal K Bhatia
- Section of Cardiac Electrophysiology, Emory University School of Medicine, Atlanta, GA (R.I., M.L., N.K.B., F.M.M.)
| | - Laith Alkukhun
- Knight Cardiovascular Institute, Oregon Health and Science University, Portland (L.A., B.N.)
| | - Joseph Adewumi
- Division of Cardiovascular Medicine, Cardiac Electrophysiology Section, University of Colorado Anschutz Medical Campus, Aurora (J.A., W.T.)
| | - Robert D Schaller
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
| | - Francis E Marchlinski
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
| | - Benjamin D'Souza
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
| | - Babak Nazer
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
- Knight Cardiovascular Institute, Oregon Health and Science University, Portland (L.A., B.N.)
| | - Wendy Tzou
- Division of Cardiovascular Medicine, Cardiac Electrophysiology Section, University of Colorado Anschutz Medical Campus, Aurora (J.A., W.T.)
| | - Faisal M Merchant
- Section of Cardiac Electrophysiology, Emory University School of Medicine, Atlanta, GA (R.I., M.L., N.K.B., F.M.M.)
| | - David S Frankel
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (A.S., R.D.S., F.E.M., B.D., B.N., D.S.F.)
| |
Collapse
|
2
|
Sampognaro JR, Karatela M, Lewis RK, Black-Maier E, Pokorney SD, Hegland DD, Piccini JP. Efficacy and Safety of Adjunctive and Primary Use of the TightRail Mechanical Cutting Sheath for Lead Extraction. Circ Arrhythm Electrophysiol 2023:e011603. [PMID: 37264920 DOI: 10.1161/circep.122.011603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Rotational cutting tools are increasingly used in transvenous lead extraction. There are limited data on their safety and efficacy, particularly when used adjunctively for stalled progression. The aim of this study was to evaluate the utilization, safety, and effectiveness of mechanical rotational cutting tools for transvenous lead extraction. METHODS Patients undergoing transvenous lead extraction at a single tertiary center (April 2015 to January 2021, n=586) were included in this retrospective analysis. The study characterized the 251 patients (42.8%) whose cases involved the TightRail mechanical cutting tool. RESULTS Among 251 patients, 526 leads were extracted and TightRail was used for 70.5%. The TightRail was used adjunctively with the laser for 65.2% of leads, 97.8% of the time as the second tool after stalled progression. Using a multivariable logistic regression model, we found that active-fixation leads (odds ratio, 2.78 [95% CI, 1.62-4.78]; P=0.0002), dual-coil leads (odds ratio, 3.39 [95% CI, 1.87-6.16]; P<0.0001), and lead dwell time (odds ratio, 1.16 [95% CI for 1-year increase, 1.11-1.21]; P<0.0001) were factors independently associated with adjunctive TightRail use. Stalled progression requiring TightRail occurred most often in the innominate vein and superior vena cava (59.3%). The clinical success rate was 96.8%, and the rate of major adverse events was 2.8%. Only 1 major adverse event was observed during TightRail use. CONCLUSIONS Rotational cutting with TightRail was used in 42.8% of transvenous lead extractions, predominantly in an adjunctive manner after stalled laser progression in the innominate vein and superior vena cava, and more frequently for dual-coil and leads with longer dwell times. Adjunctive TightRail use carries a low risk of major complications.
Collapse
Affiliation(s)
- James R Sampognaro
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Maham Karatela
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Robert K Lewis
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Eric Black-Maier
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Sean D Pokorney
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Donald D Hegland
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| | - Jonathan P Piccini
- Cardiac Electrophysiology Section, Division of Cardiology, Duke University Medical Center & the Duke Clinical Research Institute, Durham, NC
| |
Collapse
|
3
|
Gasperetti A, Carrick RT, Costa S, Compagnucci P, Bosman LP, Chivulescu M, Tichnell C, Murray B, Tandri H, Tadros R, Rivard L, van den Berg MP, Zeppenfeld K, Wilde AA, Pompilio G, Carbucicchio C, Dello Russo A, Casella M, Svensson A, Brunckhorst CB, van Tintelen JP, Platonov PG, Haugaa KH, Duru F, te Riele AS, Khairy P, Tondo C, Calkins H, James CA, Saguner AM, Cadrin-Tourigny J. Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Study. Circulation 2022; 146:1434-1443. [PMID: 36205131 PMCID: PMC9640278 DOI: 10.1161/circulationaha.122.060866] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND A novel risk calculator based on clinical characteristics and noninvasive tests that predicts the onset of clinical sustained ventricular arrhythmias (VA) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has been proposed and validated by recent studies. It remains unknown whether programmed ventricular stimulation (PVS) provides additional prognostic value. METHODS All patients with a definite ARVC diagnosis, no history of sustained VAs at diagnosis, and PVS performed at baseline were extracted from 6 international ARVC registries. The calculator-predicted risk for sustained VA (sustained or implantable cardioverter defibrillator treated ventricular tachycardia [VT] or fibrillation, [aborted] sudden cardiac arrest) was assessed in all patients. Independent and combined performance of the risk calculator and PVS on sustained VA were assessed during a 5-year follow-up period. RESULTS Two hundred eighty-eight patients (41.0±14.5 years, 55.9% male, right ventricular ejection fraction 42.5±11.1%) were enrolled. At PVS, 137 (47.6%) patients had inducible ventricular tachycardia. During a median of 5.31 [2.89-10.17] years of follow-up, 83 (60.6%) patients with a positive PVS and 37 (24.5%) with a negative PVS experienced sustained VA (P<0.001). Inducible ventricular tachycardia predicted clinical sustained VA during the 5-year follow-up and remained an independent predictor after accounting for the calculator-predicted risk (HR, 2.52 [1.58-4.02]; P<0.001). Compared with ARVC risk calculator predictions in isolation (C-statistic 0.72), addition of PVS inducibility showed improved prediction of VA events (C-statistic 0.75; log-likelihood ratio for nested models, P<0.001). PVS inducibility had a 76% [67-84] sensitivity and 68% [61-74] specificity, corresponding to log-likelihood ratios of 2.3 and 0.36 for inducible (likelihood ratio+) and noninducible (likelihood ratio-) patients, respectively. In patients with a ARVC risk calculator-predicted risk of clinical VA events <25% during 5 years (ie, low/intermediate subgroup), PVS had a 92.6% negative predictive value. CONCLUSIONS PVS significantly improved risk stratification above and beyond the calculator-predicted risk of VA in a primary prevention cohort of patients with ARVC, mainly for patients considered to be at low and intermediate risk by the clinical risk calculator.
Collapse
Affiliation(s)
- Alessio Gasperetti
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Richard T. Carrick
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Sarah Costa
- Department of Cardiology, University Heart Center Zurich, University Hospital Zurich‚ Switzerland (S.C., C.B.B., F.D., A.M.S.)
| | - Paolo Compagnucci
- Cardiology and Arrhythmology Clinic, University Hospital Umberto-I-Salesi-Lancisi, Ancona, Italy (P.C., A.D.R., M. Casella)
| | - Laurens P. Bosman
- Department of Cardiology (L.P.B., A.S.J.M.t.R.), University Medical Center Utrecht, University of Utrecht, The Netherlands
| | - Monica Chivulescu
- ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway and University of Oslo (M. Chivulescu, K.H.H.)
| | - Crystal Tichnell
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Brittney Murray
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Harikrishna Tandri
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Rafik Tadros
- Cardiovascular Genetics Center and Electrophysiology Service, Montreal Heart Institute, Université de Montréal, Canada (R.T., L.R., P.K., J.C.-T.)
| | - Lena Rivard
- Cardiovascular Genetics Center and Electrophysiology Service, Montreal Heart Institute, Université de Montréal, Canada (R.T., L.R., P.K., J.C.-T.)
| | - Maarten P. van den Berg
- Department of Cardiology, University Medical Center Groningen, University of Groningen‚ The Netherlands (M.P.v.d.B.)
| | - Katja Zeppenfeld
- Department of Cardiology, Leiden University Medical Center, The Netherlands (K.Z.)
| | - Arthur A.M. Wilde
- Amsterdam UMC location University of Amsterdam‚ Department of Cardiology‚ Amsterdam‚ The Netherlands (A.A.M.W.)
| | | | - Corrado Carbucicchio
- Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Department of Clinical Electrophisiology and Cardiac Pacing, Milan, Italy (C.C., C. Tondo)
| | - Antonio Dello Russo
- Cardiology and Arrhythmology Clinic, University Hospital Umberto-I-Salesi-Lancisi, Ancona, Italy (P.C., A.D.R., M. Casella)
| | - Michela Casella
- Cardiology and Arrhythmology Clinic, University Hospital Umberto-I-Salesi-Lancisi, Ancona, Italy (P.C., A.D.R., M. Casella)
| | - Anneli Svensson
- Department of Cardiology and Department of Health‚ Medicine and Caring Sciences‚ Linköping University‚ Sweden (A.S.)
| | - Corinna B. Brunckhorst
- Department of Cardiology, University Heart Center Zurich, University Hospital Zurich‚ Switzerland (S.C., C.B.B., F.D., A.M.S.)
| | - J. Peter van Tintelen
- Department of Genetics (J.P.v.T.), University Medical Center Utrecht, University of Utrecht, The Netherlands
| | - Pyotr G. Platonov
- Department of Cardiology, Clinical Sciences, Lund University, Sweden (P.G.P.)
| | - Kristina H. Haugaa
- ProCardio Center for Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway and University of Oslo (M. Chivulescu, K.H.H.)
| | - Firat Duru
- Department of Cardiology, University Heart Center Zurich, University Hospital Zurich‚ Switzerland (S.C., C.B.B., F.D., A.M.S.)
| | - Anneline S.J.M. te Riele
- Department of Cardiology (L.P.B., A.S.J.M.t.R.), University Medical Center Utrecht, University of Utrecht, The Netherlands
| | - Paul Khairy
- Cardiovascular Genetics Center and Electrophysiology Service, Montreal Heart Institute, Université de Montréal, Canada (R.T., L.R., P.K., J.C.-T.)
| | - Claudio Tondo
- Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Department of Clinical Electrophisiology and Cardiac Pacing, Milan, Italy (C.C., C. Tondo).,Department Biomedical, Surgical and Dental Sciences, University of Milan, Italy (C. Tondo)
| | - Hugh Calkins
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Cynthia A. James
- Department of Medicine, Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD (A.G., R.T.C., C. Tichnell, B.M., H.T., H.C., C.A.J.)
| | - Ardan M. Saguner
- Department of Cardiology, University Heart Center Zurich, University Hospital Zurich‚ Switzerland (S.C., C.B.B., F.D., A.M.S.)
| | - Julia Cadrin-Tourigny
- Cardiovascular Genetics Center and Electrophysiology Service, Montreal Heart Institute, Université de Montréal, Canada (R.T., L.R., P.K., J.C.-T.)
| |
Collapse
|
4
|
Butt JH, Yafasova A, Elming MB, Dixen U, Nielsen JC, Haarbo J, Videbæk L, Korup E, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Thune JJ, Køber L. Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial. Circ Heart Fail 2022; 15:e009669. [PMID: 35942877 DOI: 10.1161/circheartfailure.122.009669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Men and women may respond differently to certain therapies for heart failure with reduced ejection fraction, including implantable cardioverter defibrillators (ICD). In an extended follow-up study of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of additional follow-up, we examined the effect of ICD implantation according to sex. METHODS In the DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD (N=556) or usual clinical care (N=550). The primary outcome was all-cause mortality. RESULTS Of the 1116 patients randomized in the DANISH trial, 307 (27.5%) were women. During a median follow-up of 9.5 years, women had a lower associated rate of all-cause mortality (hazard ratio [HR], 0.60 [95% CI, 0.47-0.78]) cardiovascular death (HR, 0.62 [95% CI, 0.46-0.84]), nonsudden cardiovascular death (HR, 0.59 [95% CI, 0.42-0.85]), and a numerically lower rate of sudden cardiovascular death (HR, 0.70 [95% CI, 0.40-1.25]), compared with men. Compared with usual clinical care, ICD implantation did not reduce the rate of all-cause mortality, irrespective of sex (men, HR, 0.85 [95% CI, 0.69-1.06]; women, HR, 0.98 [95% CI, 0.64-1.50]; Pinteraction=0.51). In addition, sex did not modify the effect of ICD implantation on sudden cardiovascular death (men, HR, 0.57 [95% CI, 0.36-0.92]; women, HR, 0.68 [95% CI, 0.26-1.77]; Pinteraction=0.76). CONCLUSIONS In patients with nonischemic systolic heart failure, ICD implantation did not provide an overall survival benefit, but reduced sudden cardiovascular death, irrespective of sex. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT00542945.
Collapse
Affiliation(s)
- Jawad H Butt
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.)
| | - Adelina Yafasova
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.)
| | - Marie B Elming
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Internal Medicine (M.B.E.), Zealand University Hospital, Roskilde, Denmark
| | - Ulrik Dixen
- Department of Cardiology, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark (U.D.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| | - Jens C Nielsen
- Department of Cardiology, Aarhus University Hospital, Denmark (J.C.N., H.E.).,Department of Clinical Medicine, Aarhus University, Denmark (J.C.N.)
| | - Jens Haarbo
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark (J.H.)
| | - Lars Videbæk
- Department of Cardiology, Odense University Hospital, Svendborg, Denmark (L.V., K.E.)
| | - Eva Korup
- Department of Cardiology, Aalborg University Hospital, Denmark (E.K., N.E.B., A.M.T.)
| | - Niels E Bruun
- Department of Cardiology (N.E.B.), Zealand University Hospital, Roskilde, Denmark.,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.).,Department of Cardiology, Aalborg University Hospital, Denmark (E.K., N.E.B., A.M.T.).,Department of Clinical Medicine, University of Aalborg, Denmark (N.E.B.)
| | - Hans Eiskjær
- Department of Cardiology, Aarhus University Hospital, Denmark (J.C.N., H.E.)
| | - Axel Brandes
- Department of Cardiology, Odense University Hospital, Denmark (A.B.).,Department of Clinical Research, University of Southern Denmark, Odense, Denmark (A.B.).,Department of Cardiology, University Hospital of Southern Denmark, Esbjerg, Denmark (A.B.)
| | - Anna M Thøgersen
- Department of Cardiology, Aalborg University Hospital, Denmark (E.K., N.E.B., A.M.T.)
| | - Finn Gustafsson
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| | - Kenneth Egstrup
- Department of Cardiology, Odense University Hospital, Svendborg, Denmark (L.V., K.E.)
| | - Christian Hassager
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| | - Jesper Hastrup Svendsen
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| | - Dan E Høfsten
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| | - Christian Torp-Pedersen
- Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.).,Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark (C.T.-P.)
| | - Steen Pehrson
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.)
| | - Jens Jakob Thune
- Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.).,Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Denmark (J.J.T.)
| | - Lars Køber
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark (J.H.B., A.Y., M.B.E., F.G., C.H., J.H.S., D.E.H., S.P., L.K.).,Department of Clinical Medicine, University of Copenhagen, Denmark (U.D., N.E.B., F.G., C.H., J.H.S., D.E.H., C.T.-P., J.J.T., L.K.)
| |
Collapse
|
5
|
Bianchi V, Bisignani G, Migliore F, Biffi M, Nigro G, Viani S, Caravati F, Checchi L, Francia P, De Filippo P, Pecora D, Lavalle C, Scalone A, Rossi P, Palmisano P, Licciardello G, Ospizio R, Lovecchio M, Valsecchi S, D'Onofrio A. Safety of Omitting Defibrillation Efficacy Testing With Subcutaneous Defibrillators: A Propensity-Matched Case-Control Study. Circ Arrhythm Electrophysiol 2021; 14:e010381. [PMID: 34852635 DOI: 10.1161/circep.121.010381] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Valter Bianchi
- "Unità Operativa di Elettrofisiologia, Studio e Terapia delle Aritmie", Monaldi Hospital, Naples, Italy (V.B., A.D.)
| | | | - Federico Migliore
- Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy (F.M.)
| | - Mauro Biffi
- Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Policlinico S.Orsola-Malpighi, Italy (M.B.)
| | - Gerardo Nigro
- Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Monaldi Hospital, Naples, Italy (G.N.)
| | - Stefano Viani
- Second Cardiology Division, Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Italy (S.V.)
| | | | | | - Pietro Francia
- Division of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University, St. Andrea Hospital, Rome, Italy (P.F.)
| | | | - Domenico Pecora
- Unità di Elettrofisiologia, Dipartimento Cardiovascolare, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy (D.P.)
| | - Carlo Lavalle
- Department of Cardiovascular Disease, Policlinico Umberto I Hospital, Rome, Italy (C.L.)
| | | | | | | | | | | | | | | | - Antonio D'Onofrio
- "Unità Operativa di Elettrofisiologia, Studio e Terapia delle Aritmie", Monaldi Hospital, Naples, Italy (V.B., A.D.)
| | | |
Collapse
|
6
|
Polcwiartek C, Loewenstein D, Friedman DJ, Johansson KG, Graff C, Sørensen PL, Nielsen RE, Kragholm K, Torp-Pedersen C, Søgaard P, Jensen SE, Jackson KP, Atwater BD. Clinical Heart Failure Among Patients With and Without Severe Mental Illness and the Association With Long-Term Outcomes. Circ Heart Fail 2021; 14:e008364. [PMID: 34587762 DOI: 10.1161/circheartfailure.121.008364] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND Patients with severe mental illness (SMI) including schizophrenia, bipolar disorder, and severe depression have earlier onset of cardiovascular risk factors, predisposing to worse future heart failure (HF) compared with the general population. We investigated associations between the presence/absence of SMI and long-term HF outcomes. METHODS We identified patients with HF with and without SMI in the Duke University Health System from 2002 to 2017. Using multivariable Cox regression, we examined the primary outcome of all-cause mortality. Secondary outcomes included rates of implantable cardioverter defibrillator use, cardiac resynchronization therapy, left ventricular assist device implantation, and heart transplantation. RESULTS We included 20 906 patients with HF (SMI, n=898; non-SMI, n=20 008). Patients with SMI presented clinically 7 years earlier than those without SMI. We observed an interaction between SMI and sex on all-cause mortality (P=0.002). Excess mortality was observed among men with SMI compared with men without SMI (hazard ratio, 1.36 [95% CI, 1.17-1.59]). No association was observed among women with and without SMI (hazard ratio, 0.97 [95% CI, 0.84-1.12]). Rates of implantable cardioverter defibrillator use, cardiac resynchronization therapy, left ventricular assist device implantation, and heart transplantation were similar between patients with and without SMI (6.1% versus 7.9%, P=0.095). Patients with SMI receiving these procedures for HF experienced poorer prognosis than those without SMI (hazard ratio, 2.12 [95% CI, 1.08-4.15]). CONCLUSIONS SMI was associated with adverse HF outcome among men and not women. Despite equal access to procedures for HF between patients with and without SMI, those with SMI experienced excess postprocedural mortality. Our data highlight concurrent sex- and mental health-related disparities in HF prognosis, suggesting that patients with SMI, especially men, merit closer follow-up.
Collapse
Affiliation(s)
- Christoffer Polcwiartek
- Division of Cardiology, Duke University Medical Center, Durham, NC (C.P., D.L., K.P.J., B.D.A.).,Department of Cardiology (C.P., K.K., C.T.-P., P.S., S.E.J.), Aalborg University Hospital, Denmark.,Department of Clinical Medicine (C.P., R.E.N., P.S., S.E.J.), Aalborg University, Denmark
| | - Daniel Loewenstein
- Division of Cardiology, Duke University Medical Center, Durham, NC (C.P., D.L., K.P.J., B.D.A.).,Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden (D.L., K.G.J.)
| | - Daniel J Friedman
- Section of Cardiac Electrophysiology, Yale School of Medicine, New Haven, CT (D.J.F.)
| | - Karin G Johansson
- Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden (D.L., K.G.J.)
| | - Claus Graff
- Department of Health Science and Technology (C.G., P.L.S.), Aalborg University, Denmark
| | - Peter L Sørensen
- Department of Health Science and Technology (C.G., P.L.S.), Aalborg University, Denmark.,Department of Clinical Physiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden (D.L., K.G.J.)
| | - René E Nielsen
- Department of Psychiatry (R.E.N.), Aalborg University Hospital, Denmark.,Department of Clinical Medicine (C.P., R.E.N., P.S., S.E.J.), Aalborg University, Denmark
| | - Kristian Kragholm
- Department of Cardiology (C.P., K.K., C.T.-P., P.S., S.E.J.), Aalborg University Hospital, Denmark
| | - Christian Torp-Pedersen
- Department of Cardiology (C.P., K.K., C.T.-P., P.S., S.E.J.), Aalborg University Hospital, Denmark.,Department of Cardiology and Clinical Research, Nordsjællands Hospital, Hillerød, Denmark (C.T.-P.)
| | - Peter Søgaard
- Department of Cardiology (C.P., K.K., C.T.-P., P.S., S.E.J.), Aalborg University Hospital, Denmark.,Department of Clinical Medicine (C.P., R.E.N., P.S., S.E.J.), Aalborg University, Denmark
| | - Svend E Jensen
- Department of Cardiology (C.P., K.K., C.T.-P., P.S., S.E.J.), Aalborg University Hospital, Denmark.,Department of Clinical Medicine (C.P., R.E.N., P.S., S.E.J.), Aalborg University, Denmark
| | - Kevin P Jackson
- Division of Cardiology, Duke University Medical Center, Durham, NC (C.P., D.L., K.P.J., B.D.A.)
| | - Brett D Atwater
- Division of Cardiology, Duke University Medical Center, Durham, NC (C.P., D.L., K.P.J., B.D.A.).,Section of Cardiac Electrophysiology, Inova Heart and Vascular Institute, Fairfax, VA (B.D.A.)
| |
Collapse
|
7
|
Atwater BD, Li Z, Pritchard J, Greiner MA, Nabutovsky Y, Hammill BG. Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. Circ Cardiovasc Qual Outcomes 2021; 14:e007580. [PMID: 34284598 DOI: 10.1161/circoutcomes.120.007580] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Increased physical activity (PA) through cardiac rehabilitation (CR) improves outcomes in patients with heart failure and coronary disease, but CR referral remains infrequent. Implantable cardioverter-defibrillators (ICDs) can provide daily PA measurements to patients that may motivate them to increase PA, but it remains unclear if increased ICD measured PA is associated with improved outcomes with and without CR. METHODS This is a retrospective observational study of 41 731 Medicare beneficiaries with ICD implantation between January 1, 2014 and December 31, 2016. We linked daily ICD PA measurements and Medicare claims data to determine if increased PA is associated with a reduction in the likelihood of death or heart failure hospitalization. To determine if CR participation altered the effect of PA on outcomes, we performed two additional analyses matching CR participants and nonparticipants using propensity scores. The first match included demographics, comorbidities, and baseline PA measurements. The second match also included the change in PA measured during CR or the same time frame after ICD implant among nonparticipants. RESULTS The mean age was 75 (SD, 10) years, 30 182 beneficiaries (72.3%) were male, and 1324 (3%) participated in CR. Increased ICD detected PA was associated with improved survival. CR participants had a mean PA change of +9.7 (SD, 57.8) min/d, whereas nonparticipants had a mean change of -1.0 (SD, 59.7) min/d (P<0.001). After matching for demographics, comorbidities and baseline PA, CR participants had significantly lower 1- to 3-year mortality (hazard ratio, 0.76 [95% CI, 0.69-0.85], P=0.03). After additionally matching for the ICD measured change in PA during CR there were no differences in mortality with and without CR (hazard ratio, 1.00 [95% CI, 0.82-1.21], P=0.87). Every 10 minutes of increased daily PA was associated with a 1.1% reduction in all-cause mortality in both groups. CONCLUSIONS Among Medicare beneficiaries with ICDs, small increases in PA were associated with significant reductions in all-cause mortality.
Collapse
Affiliation(s)
- Brett D Atwater
- Inova Heart and Vascular Institute, Fairfax, VA (B.D.A.).,Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC (B.D.A.)
| | - Zhen Li
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (Z.L., J.P., M.A.G., B.G.H.)
| | - Jessica Pritchard
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (Z.L., J.P., M.A.G., B.G.H.)
| | - Melissa A Greiner
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (Z.L., J.P., M.A.G., B.G.H.)
| | | | - Bradley G Hammill
- Department of Population Health Sciences, Duke University School of Medicine, Durham, NC (Z.L., J.P., M.A.G., B.G.H.)
| |
Collapse
|
8
|
Zweerink A, Friedman DJ, Klem I, van de Ven PM, Vink C, Biesbroek PS, Hansen SM, Kim RJ, van Rossum AC, Atwater BD, Allaart CP, Nijveldt R. Segment Length in Cine Strain Analysis Predicts Cardiac Resynchronization Therapy Outcome Beyond Current Guidelines. Circ Cardiovasc Imaging 2021; 14:e012350. [PMID: 34287001 DOI: 10.1161/circimaging.120.012350] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Patients with a class I recommendation for cardiac resynchronization therapy (CRT) are likely to benefit, but the effect of CRT in class II patients is more heterogeneous and additional selection parameters are needed in this group. The recently validated segment length in cine strain analysis of the septum (SLICE-ESSsep) measurement on cardiac magnetic resonance cine imaging predicts left ventricular functional recovery after CRT but its prognostic value is unknown. This study sought to evaluate the prognostic value of SLICE-ESSsep for clinical outcome after CRT. METHODS Two hundred eighteen patients with a left bundle branch block or intraventricular conduction delay and a class I or class II indication for CRT who underwent preimplantation cardiovascular magnetic resonance examination were enrolled. SLICE-ESSsep was manually measured on standard cardiovascular magnetic resonance cine imaging. The primary combined end point was all-cause mortality, left ventricular assist device, or heart transplantation. Secondary end points were (1) appropriate implantable cardioverter defibrillator therapy and (2) heart failure hospitalization. RESULTS Two-thirds (65%) of patients had a positive SLICE-ESSsep ≥0.9% (ie, systolic septal stretching). During a median follow-up of 3.8 years, 66 (30%) patients reached the primary end point. Patients with positive SLICE-ESSsep were at lower risk to reach the primary end point (hazard ratio 0.36; P<0.001) and heart failure hospitalization (hazard ratio 0.41; P=0.019), but not for implantable cardioverter defibrillator therapy (hazard ratio, 0.66; P=0.272). Clinical outcome of class II patients with a positive ESSsep was similar to those of class I patients (hazard ratio, 1.38 [95% CI, 0.66-2.88]; P=0.396). CONCLUSIONS Strain assessment of the septum (SLICE-ESSsep) provides a prognostic measure for clinical outcome after CRT. Detection of a positive SLICE-ESSsep in patients with a class II indication predicts improved CRT outcome similar to those with a class I indication whereas SLICE-ESSsep negative patients have poor prognosis after CRT implantation.
Collapse
Affiliation(s)
- Alwin Zweerink
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | - Daniel J Friedman
- Section of Cardiac Electrophysiology, Yale School of Medicine, New Haven, CT (D.J.F., R.J.K.)
| | - Igor Klem
- Division of Cardiology, Duke University Medical Center, Durham, NC (I.K.)
| | - Peter M van de Ven
- Department of Epidemiology and Biostatistics (P.M.v.d.V.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | - Caitlin Vink
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | - P Stefan Biesbroek
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | - Steen M Hansen
- Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Denmark (S.M.H.)
| | - Raymond J Kim
- Section of Cardiac Electrophysiology, Yale School of Medicine, New Haven, CT (D.J.F., R.J.K.)
| | - Albert C van Rossum
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | | | - Cornelis P Allaart
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands
| | - Robin Nijveldt
- Department of Cardiology, and Amsterdam Cardiovascular Sciences (ACS) (A.Z., C.V., P.S.B., A.C.v.R., C.P.A., R.N.), Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands.,Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands (R.N.)
| |
Collapse
|
9
|
Calò L, Bianchi V, Ferraioli D, Santini L, Dello Russo A, Carriere C, Santobuono VE, Andreoli C, La Greca C, Arena G, Talarico A, Pisanò E, Santoro A, Giammaria M, Ziacchi M, Viscusi M, De Ruvo E, Campari M, Valsecchi S, D'Onofrio A. Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice. Circ Heart Fail 2021; 14:e008134. [PMID: 34190592 PMCID: PMC8522625 DOI: 10.1161/circheartfailure.120.008134] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND The HeartLogic algorithm combines multiple implantable cardioverter-defibrillator sensors to identify patients at risk of heart failure (HF) events. We sought to evaluate the risk stratification ability of this algorithm in clinical practice. We also analyzed the alert management strategies adopted in the study group and their association with the occurrence of HF events. METHODS The HeartLogic feature was activated in 366 implantable cardioverter-defibrillator and cardiac resynchronization therapy implantable cardioverter-defibrillator patients at 22 centers. The median follow-up was 11 months [25th-75th percentile: 6-16]. The HeartLogic algorithm calculates a daily HF index and identifies periods IN alert state on the basis of a configurable threshold. RESULTS The HeartLogic index crossed the threshold value 273 times (0.76 alerts/patient-year) in 150 patients. The time IN alert state was 11% of the total observation period. Patients experienced 36 HF hospitalizations, and 8 patients died of HF during the observation period. Thirty-five events were associated with the IN alert state (0.92 events/patient-year versus 0.03 events/patient-year in the OUT of alert state). The hazard ratio in the IN/OUT of alert state comparison was (hazard ratio, 24.53 [95% CI, 8.55-70.38], P<0.001), after adjustment for baseline clinical confounders. Alerts followed by clinical actions were associated with less HF events (hazard ratio, 0.37 [95% CI, 0.14-0.99], P=0.047). No differences in event rates were observed between in-office and remote alert management. CONCLUSIONS This multiparametric algorithm identifies patients during periods of significantly increased risk of HF events. The rate of HF events seemed lower when clinical actions were undertaken in response to alerts. Extra in-office visits did not seem to be required to effectively manage HeartLogic alerts. REGISTRATION URL: https://www.clinicaltrials.gov; Unique identifier: NCT02275637.
Collapse
Affiliation(s)
- Leonardo Calò
- Cardiology Department, Policlinico Casilino, Rome, Italy (L.C., E.D.R.)
| | - Valter Bianchi
- Unità Operativa di Elettrofisiologia, Studio e Terapia delle Aritmie," Monaldi Hospital, Naples, Italy (V.B., A.D.)
| | - Donatella Ferraioli
- Cardiology Department, OO.RR. San Giovanni di Dio Ruggi d'Aragona, Salerno, Italy (D.F.)
| | - Luca Santini
- Cardiology Department, "Giovan Battista Grassi" Hospital, Rome, Italy (L.S.)
| | - Antonio Dello Russo
- Clinica di Cardiologia e Aritmologia, Università Politecnica delle Marche, "Ospedali Riuniti," Ancona, Italy (A.D.R.)
| | - Cosimo Carriere
- Cardiology Department, Azienda Ospedaliera Universitaria Ospedali Riuniti di Trieste - Cattinara, Trieste, Italy (C.C.)
| | | | - Chiara Andreoli
- Cardiology Department, S. Giovanni Battista Hospital, Foligno, Italy (C.A.)
| | - Carmelo La Greca
- Cardiology Department, Fondazione Poliambulanza, Brescia, Italy (C.L.G.)
| | - Giuseppe Arena
- Cardiology Department, Ospedale Civile Apuane, Massa, Italy (G.A.)
| | | | - Ennio Pisanò
- Cardiology Department, Vito Fazzi Hospital, Lecce, Italy (E.P.)
| | - Amato Santoro
- Cardiology Department, Azienda Ospedaliera Universitaria Senese, Policlinico Santa Maria alle Scotte, Siena, Italy (A.S.)
| | - Massimo Giammaria
- Division of Cardiology, Maria Vittoria Hospital, Turin, Italy (M.G.)
| | - Matteo Ziacchi
- Institute of Cardiology, University of Bologna, S.Orsola-Malpighi University Hospital, Italy (M.Z.)
| | - Miguel Viscusi
- Cardiology Department, S. Anna e S. Sebastiano Hospital, Caserta, Italy (M.V.)
| | | | - Monica Campari
- Rhythm Management Department, Boston Scientific Italia, Milan, Italy (M.C., S.V.)
| | - Sergio Valsecchi
- Rhythm Management Department, Boston Scientific Italia, Milan, Italy (M.C., S.V.)
| | - Antonio D'Onofrio
- Unità Operativa di Elettrofisiologia, Studio e Terapia delle Aritmie," Monaldi Hospital, Naples, Italy (V.B., A.D.)
| | | |
Collapse
|
10
|
Affiliation(s)
- Bryce Alexander
- Division of Cardiology, Queen's University, Kingston, Ontario, Canada
| | - Adrian Baranchuk
- Division of Cardiology, Queen's University, Kingston, Ontario, Canada
| |
Collapse
|
11
|
Lacour P, Buschmann C, Storm C, Nee J, Parwani AS, Huemer M, Attanasio P, Boldt LH, Rauch G, Kucher A, Pieske B, Haverkamp W, Blaschke F. Cardiac Implantable Electronic Device Interrogation at Forensic Autopsy: An Underestimated Resource? Circulation 2019; 137:2730-2740. [PMID: 29915100 DOI: 10.1161/circulationaha.117.032367] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 04/24/2018] [Indexed: 11/16/2022]
Abstract
BACKGROUND Postmortem interrogations of cardiac implantable electronic devices (CIEDs), recommended at autopsy in suspected cases of sudden cardiac death, are rarely performed, and data on systematic postmortem CIED analysis in the forensic pathology are missing. The aim of the study was to determine whether nonselective postmortem CIED interrogations and data analysis are useful to the forensic pathologist to determine the cause, mechanism, and time of death and to detect potential CIED-related safety issues. METHODS From February 2012 to April 2017, all autopsy subjects in the department of forensic medicine at the University Hospital Charité who had a CIED underwent device removal and interrogation. Over the study period, 5368 autopsies were performed. One hundred fifty subjects had in total 151 CIEDs, including 109 pacemakers, 35 defibrillators, and 7 implantable loop recorders. RESULTS In 40 cases (26.7%) time of death and in 51 cases (34.0%) cause of death could not be determined by forensic autopsy. Of these, CIED interrogation facilitated the determination of time of death in 70.0% of the cases and clarified the cause of death in 60.8%. Device concerns were identified in 9 cases (6.0%), including 3 hardware, 4 programming, and 2 algorithm issues. One CIED was submitted to the manufacturer for a detailed technical analysis. CONCLUSIONS Our data demonstrate the necessity of systematic postmortem CIED interrogation in forensic medicine to determine the cause and timing of death more accurately. In addition, CIED analysis is an important tool to detect potential CIED-related safety issues.
Collapse
Affiliation(s)
- Philipp Lacour
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Claas Buschmann
- Campus Virchow-Klinikum, Germany. Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Legal Medicine and Forensic Sciences, Campus Mitte, Germany (C.B.)
| | - Christian Storm
- Department of Nephrology and Intensive Care Medicine (C.S., J.N.)
| | - Jens Nee
- Department of Nephrology and Intensive Care Medicine (C.S., J.N.)
| | - Abdul Shokor Parwani
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Martin Huemer
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Philipp Attanasio
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Leif-Hendrik Boldt
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Geraldine Rauch
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Germany (G.R.)
| | | | - Burkert Pieske
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Wilhelm Haverkamp
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| | - Florian Blaschke
- Charité-Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Cardiology (P.L., A.S.P., M.H., P.A., L.-H.B., B.P., W.H., F.B.)
| |
Collapse
|
12
|
Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, Zareba W, Goldenberg I. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015; 132:1613-9. [PMID: 26316618 DOI: 10.1161/circulationaha.115.015677] [Citation(s) in RCA: 168] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Accepted: 08/13/2015] [Indexed: 12/14/2022]
Abstract
BACKGROUND Prospective data on the safety and efficacy of the wearable cardioverter defibrillator (WCD) in a real-world setting are lacking. The Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II) Registry was designed to provide real-world data on the WCD as a strategy during a period of risk stratification. METHODS AND RESULTS The WEARIT-II Registry enrolled 2000 patients with ischemic (n=805, 40%), or nonischemic cardiomyopathy (n=927, 46%), or congenital/inherited heart disease (n=268) prescribed WCD between August 2011 and February 2014. Clinical data, arrhythmia events, implantable cardioverter defibrillator implantation, and improvement in ejection fraction were captured. The median age was 62 years; the median ejection fraction was 25%. The median WCD wear time was 90 days, with median daily use of 22.5 hours. There was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54% received appropriate WCD shock. Only 10 patients (0.5%) received inappropriate WCD therapy. The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among patients with ischemic cardiomyopathy and congenital/inherited heart disease, and 1% among nonischemic patients (P=0.02). At the end of WCD use, 840 patients (42%) were implanted with an implantable cardioverter defibrillator. The most frequent reason not to implant an implantable cardioverter defibrillator following WCD use was improvement in ejection fraction. CONCLUSIONS The WEARIT-II Registry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD can be safely used to protect patients during this period of risk assessment.
Collapse
Affiliation(s)
- Valentina Kutyifa
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY.
| | - Arthur J Moss
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Helmut Klein
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Yitschak Biton
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Scott McNitt
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Bonnie MacKecknie
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Wojciech Zareba
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| | - Ilan Goldenberg
- From University of Rochester Medical Center, Cardiology Division, Heart Research Follow-up Program, Rochester, NY
| |
Collapse
|
13
|
Abstract
This case highlights the importance of considering a wide differential diagnosis in a young patient with chest pain and an abnormal ECG. Rarer causes of myocarditis such as GCM should be sought in patients who develop ventricular arrhythmias or high-grade heart block because the treatment is different and dramatically influences outcome. Our patient is the first reported case of GCM and a concurrent diagnosis of tuberculosis. It is most likely that the histological appearance of GCM was due to the presence of mycobacterial infection within the myocardium, and we believe that effective antituberculous therapy has led to resolution of the GCM without the need for continued long-term immunosuppression.
Collapse
|
14
|
Francis J, Niehaus M. Interference between cellular telephones and implantable rhythm devices: a review on recent papers. Indian Pacing Electrophysiol J 2006; 6:226-33. [PMID: 17031411 PMCID: PMC1586160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
BACKGROUND Cardiac pacemakers and implantable defibrillators are potentially susceptible to electromagnetic interferences as they have complex circuitry for sensing and communication purposes. Cellular telephones being an important source of electromagnetic waves are likely to cause interference in the function of these devices. METHODS A systematic analysis of studies on interaction between cellular telephones and implantable devices was done using professional databases for literature. Related articles and references of relevant articles were also searched for suitable studies. RESULTS Fourteen studies on pacemakers and eight studies on implantable defibrillators were identified. No dangerous malfunction was found in any of the analyzed studies, but most of the studies noted interference with device function when the phone was operated very close to the device. Interference was minimally in those devices with built in feed-through filters for eliminating electromagnetic interference. Device programming and interrogation were the most susceptible phases of operation. SUMMARY Cellular phones are likely to interfere with implantable rhythm devices if operated in close proximity or during programming of the device. Patients with implanted devices can safely use cellular phones if they are not carried close to the implanted devices or operated near them. Carrying the cellular phones in the belt position, receiving calls in the ear opposite to the side of the implanted device and keeping the phone as far away as possible while dialing can be considered a safe practice. Interrogation of the devices should take place exclusively in areas where utilization of cellular phones is strictly prohibited. Studies on pacemakers published in the current decade have shown much lesser rates of interference, possibly due to improvement in device technology.
Collapse
Affiliation(s)
- Johnson Francis
- Department of Cardiology, Calicut Medical College, Calicut, Kerala, India.
| | | |
Collapse
|